Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy – Pipeline Review, H2 2012

Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy - Pipeline Review, H2 2012', provides an overview of the Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy therapeutic pipeline. This report provides information on the therapeutic development for Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy. 'Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy.
- A review of the Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy pipeline depth and focus of Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy 7
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics under Investigation by Universities/Institutes 9
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics – Products under Investigation by Universities/Institutes 13
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy – Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Combination Products 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Drug Profiles 21
RAD001 + Revlimid - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Treanda + Carboplatin + Rituximab + Etoposide - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 23
RAD001 + CHOP - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 25
Busulfan + Cyclophosphamide + Allogeneic Bone Marrow Transplantation + Methylprednisolone + Methotrexate + Cyclosporine - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 27
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Tacrolimus + Mycophenolate Mofetil + Melphalan + Filgrastim + Stem Cell Transplantation + Radiation Therapy - Drug Profile 28
Product Description 28
Mechanism of Action 29
R&D Progress 30
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Cyclosporine + Mycophenolate Mofetil + Melphalan + Therapeutic Autologous Lymphocytes + Stem Cell Transplantation + Radiation Therapy - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 32
Fludarabine Phosphate + Total-Body Irradiation + Peripheral Blood Stem Cell Transplantation + Cyclosporine + Mycophenolate Mofetil - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 35
Vidaza + Velcade - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Carfilzomib - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
LBH589 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Cyclophosphamide + Etoposide + Vincristine + Prednisone + Pralatrexate - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics - Dormant Products 40
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy – Product Development Milestones 41
Featured News & Press Releases 41
Dec 07, 2010: Kyowa Hakko Kirin Announces Results From Japan Phase II Clinical Trial Of KW-0761 In Adult T-Cell Leukemia-Lymphoma 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables
Number of Products Under Development for Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy, H2 2012 7
Products under Development for Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy – Comparative Analysis, H2 2012 8
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 13
Assessment by Monotherapy Products, H2 2012 14
Assessment by Combination Products, H2 2012 15
Assessment by Stage and Route of Administration, H2 2012 17
Assessment by Stage and Molecule Type, H2 2012 20
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics – Dormant Products 40

List of Figures
Number of Products under Development for Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy, H2 2012 7
Products under Development for Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy – Comparative Analysis, H2 2012 8
Products under Investigation by Universities/Institutes, H2 2012 9
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 14
Assessment by Combination Products, H2 2012 15
Assessment by Route of Administration, H2 2012 16
Assessment by Stage and Route of Administration, H2 2012 17
Assessment by Molecule Type, H2 2012 18
Assessment by Stage and Molecule Type, H2 2012 19